BioIntelliSense, Inc’s Post

At Houston Methodist, tech-enabled innovations are transforming patient care, improving efficiency and enhancing outcomes.    Their approach to leveraging cutting-edge technologies, including the medical-grade BioButton™ wearable device, is a testament to the power of continuous monitoring and data-driven insights in improving healthcare delivery. It’s exciting to see such forward-thinking institutions embrace technologies that make a real difference in patient care.   Read more about how Houston Methodist is redesigning healthcare and reimagining the patient experience: https://lnkd.in/gSE6Ejt7   #HealthcareInnovation #PatientCare #DigitalHealth

At BioIntelliSense, we’re helping to build the blueprint for the future of tech-enabled healthcare. Today, the FDA-cleared BioButton® wearable device is continuously monitoring over 100K patients, enabling clinicians to automate vital sign collection and to enable better, safer care from in-hospital to home. BioIntelliSense CEO James Mault, MD, FACS and CCO Carolyn Walsh recently contributed their industry expertise and key learnings to help shape the Consumer Technology Association’s newest #telehealth guidelines. 

Every minute counts – especially for nurses on the floor. At Houston Methodist, continuous vital sign monitoring with the BioButton® multiparameter wearable has helped nurses redirect 15 minutes per patient, per day, where they’re needed most. What this means: for a population of 250,000 patients, that adds up to 62,000 person-dedicated hours, or just over 7 years, that can be given back to patients who need hands-on care. Read more about the impact the BioButton is having at Houston Methodist in this recent issue of Roberta Schwartz’ “Healthcare Insights from Digital Innovation Obsessed People” LinkedIn newsletter ➡ https://lnkd.in/gfnWNkbT #patientmonitoring #medtech

Read the latest from mHealthIntelligence on the growing success of our system-wide inpatient program with all 8 Houston Methodist hospitals. The FDA-cleared BioButton® wearable and continuous monitoring solution is reducing clinical staff burden by automating vital sign collection for thousands of non-ICU patients each and every day. And we’re just getting started.    Thanks for your coverage Anuja Vaidya. #RPM #healthtech #healthcareinnovation https://lnkd.in/euYM5SVE

Take a tour of Houston Methodist’s state-of-the-art “virtual care command center” where med-surg patients are centrally monitored with the BioButton® multi-parameter wearable device and BioDashboard™ clinical intelligence  solution. Sarah N Pletcher, MD MHCDS, Vice President and Executive Medical Director of Strategic Innovation at Houston Methodist, provides an inside view of the hospital system’s “Vitals Redesign” initiative leveraging the FDA-cleared BioButton device, which recently completed its expansion across all 2,653 non-ICU beds in all eight of the health system’s hospitals. https://lnkd.in/g_CAHpK5  #RPM #healthtech #healthcare

Leading hospitals & tens of thousands of patients are continuously monitored by the medical-grade BioButton from in-hospital to home. Listen to the latest about the clinical value we bring and the impact we make for providers and patients in this live interview with BioIntelliSense Founder and CEO, James Mault, MD, FACS as he talks with KMOX | Audacy news radio. Link: https://lnkd.in/g3X8ryBH #patientmonitoring #healthtech 

We're thrilled to announce that James Mault, MD, FACS, Founder and CEO of BioIntelliSense, is joining the newly formed Advisory Board of M42 Health, alongside fellow health and technology luminaries David Rhew, M.D., Microsoft Global Chief Medical Officer and VP of Healthcare; David A. Sinclair A.O., Ph.D., Professor of Epigenetics and Longevity at Harvard University; and Sir Chris Evans, Chairman of Ellipses Pharma. The new M42 Advisory Board marks a critical milestone for the Abu Dhabi-based, global tech-enabled health and healthcare company with facilities in more than 26 countries. According to M42, the new Advisory Board will “drive M42’s vision to reshape the sustainable future of health through collaboration with other regional and international industry leaders. “The Advisory Board reflects M42’s commitment to bring together traditional health-tech and healthcare provisions under a holistic ‘health’ approach, focused on preventive, precise and personalized health solutions. This pioneering approach, coupled with M42’s cutting-edge innovation and commitment to reshaping the sustainable future of health, positions it as an unparalleled force in the global health sector.” Read more in today’s announcement: https://lnkd.in/gKRCV4EX #HealthcareInnovation #HealthTech #HealthcareFuture

Today and every day: We are incredibly grateful for the dedicated and passionate nursing professionals here at BioIntelliSense and at our valued health system partners throughout the US and abroad. You inspire us with your compassion and vision as we work together to transform care delivery so that you can focus on what matters most – your patients. #NursesWeek2024 #CelebrateNurses

“Because we catch things earlier, patients are doing better, as we don’t have to wait for the bedside team to notice if something is going wrong.” - Houston Methodist’s Sarah N Pletcher, MD MHCDS, on how the BioButton wearable device and continuous monitoring solution is transforming vital sign monitoring.   Today in Fortune: Read the full story from Phil Galewitz about how the medical-grade BioButton wearable and the BioIntelliSense advanced clinical intelligence solution are improving the care experience for both patients and nurses across Houston Methodist’s 8 hospitals: https://lnkd.in/gNNBd4qj.   #futureofhealthcare #patientmonitoring #smarthospital